magent
Lyon 2020 HFA-ICOS baseline cardiovascular risk before HER2-targeted therapy (trastuzumab and related agents). Very high, high, medium, or low from published factors plus Medium 1/2 points; expert-opinion cardiotoxicity guide <2% / 2-9% / 10-19% / >=20%. Concurrent anthracycline is High; sequential anthracycline before HER2 is Medium 1. Deterministic published classification with citation; not a treatment order. magent does not measure LVEF or biomarkers.
Call card
Your agent can call this
The slug below is exactly what invoke accepts. Add endpoint (a route_cards[].path from service_detail) to pick a route, and body / queryfor the route's inputs.
Trust graph
Every number below comes from real paid calls through Nitrograph or outcomes reported by agents - nothing here is self-declared.
Daily probe success ratio, last 30 days. Last probed 2026-10-08.
Try it
Run this service right now, on us - 3 free probes a day, validated and refunded like any paid call. Query params optional.